30 closest matches · ranked by relevance
Leukemia
Primary: the Overall Survival of APL Patients Treated With Retinoic Acid Receptor Alpha (ATRA) and Arsenic Trioxide (ATO) Based Trial — 1; 0; 0; 0 participants — p=<0.05
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Childhood Acute Promyelocytic Leukemia With PML-RARA · Myeloid Neoplasm
Primary: Event-free Survival (EFS) — 95.4; 82.9 Percentage of participants
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Leukemia
Primary: Continuous Complete Remission at 3 Years — 74 percentage of participants
Leukemia
Primary: Number of Patients With Complete Remission — 3 participants
Leukemia
Primary: Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) — 6; 5; 6; 0 Participants
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 12; 2 Participants
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Leukemia of Ambiguous Lineage
Primary: Participants Complete Response — 9 Participants
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Leukemia
Primary: Continuous Complete Remission at 1 Year — 21 participants
Acute Undifferentiated Leukemia · B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I) — 30 mg
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Donor Neutrophil Engraftment — 3; 7; 1 Participants
Leukemia
Primary: Overall Response (CR for ALL Patients), (CR + CRp for AML Patients) — 1; 2; 0; 2 participants
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Relapsed/Refractory Philadelphia Positive B-precursor ALL
Primary: Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery (CR/CRh*) During the First Two Treatment Cycles — 35.6…
Leukemia
Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants
Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Primary: Maximum Tolerated Dose of 5-azacytidine in the Combination of Nivolumab With Dihydro-5-azacytidine — 75; 75; 75 Mg/m^2
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Adult Acute Myeloid Leukemia · Adult Myelodysplastic Syndrome
Primary: Rate of Hospital Admission During Outpatient Induction Chemotherapy — 3; 14 Participants
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects